top of page

Hello USA and Canada

Find the drug and healthcare news of the USA and Canada.

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Aetna Survey Highlights Evolving Payer-Provider Confidence Landscape | iPharmaCenter

FDA Approves KEYTRUDA-Padcev Combo as First Perioperative Standard for Muscle-Invasive Bladder Cancer

Medicare GLP‑1 Bridge Program: Eligibility, Costs, and Drug Details | iPharmaCenter

FDA Clears Sanofi’s Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes | iPharmaCenter

Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter

Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter

Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter

Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter

Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter

Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter

Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter

FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter

Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter

Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma

Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases

FDA Clears Wegovy Pill as First Oral GLP-1 for US Weight Management

FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

Merck and Bayer announced the US FDA approval for Verquvo

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

bottom of page